Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy
Boron neutron capture therapy (BNCT) is a non-invasive therapeutic technique for treating malignant tumors, however, methods to evaluate its therapeutic efficacy and adverse reactions are lacking. High mobility group box 1 (HMGB1) is an inflammatory molecule released during cell death. Therefore, we...
Main Authors: | Shoji Imamichi, Lichao Chen, Tasuku Ito, Ying Tong, Takae Onodera, Yuka Sasaki, Satoshi Nakamura, PierLuigi Mauri, Yu Sanada, Hiroshi Igaki, Yasufumi Murakami, Minoru Suzuki, Jun Itami, Shinichiro Masunaga, Mitsuko Masutani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/11/3/420 |
Similar Items
-
Biodistribution of <sup>10</sup>B in Glioma Orthotopic Xenograft Mouse Model after Injection of L-para-Boronophenylalanine and Sodium Borocaptate
by: Natalya V. Gubanova, et al.
Published: (2021-06-01) -
Boron Neutron Capture Therapy: A Review of Clinical Applications
by: Timothy D. Malouff, et al.
Published: (2021-02-01) -
Synthesis and Characterization of Boron Carbide Nanoparticles as Potential Boron-Rich Therapeutic Carriers
by: Dawid Kozień, et al.
Published: (2023-10-01) -
Dose Rate Effect on Cell Survival in BNCT
by: Katsumi Hirose, et al.
Published: (2023-08-01) -
A Review of Boron Neutron Capture Therapy: Its History and Current Challenges
by: Will H. Jin, MD, et al.
Published: (2022-06-01)